Wisconsin Assembly Bill AB1044

Wisconsin 2023-2024 Regular Session

• Introduced: 2/2/24
• Refer: 2/2/24
• Failed: 4/15/24

Caption

Cost-sharing cap on epinephrine auto-injectors under health insurance policies and plans.

Impact

If passed, AB1044 would amend existing health insurance statutes, specifically sections related to the coverage and cost-sharing arrangements for epinephrine auto-injectors. It would potentially alleviate financial pressure on families and individuals by establishing a maximum cost that insurance companies can charge for these essential medical devices. This change could improve compliance with treatment protocols for patients with life-threatening allergies, thereby enhancing public health outcomes across the state.

Summary

Assembly Bill 1044 aims to address the financial burden of epinephrine auto-injectors on patients in Wisconsin. The bill mandates that all health insurance policies and self-insured governmental plans that cover medically necessary epinephrine auto-injectors cannot impose a cost-sharing amount exceeding $60 for a twin-pack of these life-saving devices. This regulation applies regardless of the type of epinephrine auto-injector used, making it a significant measure intended to enhance accessibility for individuals who rely on these injectors for emergency treatment of severe allergic reactions.

Contention

While supporters of AB1044 emphasize its role in ensuring that cost does not prevent access to necessary medical treatment, there may be concerns related to the implications for insurance companies and their ability to manage risk and costs. Some stakeholders may argue that implementing such mandates could lead to higher overall premiums for consumers. Additionally, discussions regarding the fiscal impact of these regulations on state-funded insurance plans might arise, as the state reviews the financial viability of these mandated changes.